Core Viewpoint - Medicus Pharma Ltd. and Helix Nanotechnologies Inc. have entered into a non-binding memorandum of understanding (MoU) to collaborate on the development of thermostable infectious disease vaccines by integrating their proprietary technologies [1][2]. Group 1: Collaboration Details - The MoU aims to combine HelixNano's mRNA vaccine platform with Medicus' microneedle array (MNA) delivery system for the co-development and commercialization of thermostable mRNA-based vaccines [1][2]. - Both companies are engaged in good faith negotiations to form a joint venture for this purpose [2]. - The collaboration includes a project to develop clinical-grade mRNA vaccine-loaded MNAs for a Phase 1 clinical bridging study comparing intramuscular injection and intradermal MNA delivery of HelixNano's vaccine candidate HN-0001 [3]. Group 2: Technological Innovations - The combination of HelixNano's mRNA platform and Medicus' MNA technology aims to create needle-free, thermostable vaccines that could eliminate cold-chain logistics, reduce distribution costs, and improve patient access [4]. - The project is expected to position the companies at the forefront of opportunities to prevent infectious diseases rather than just treating them [4]. Group 3: Research and Development Activities - Medicus and HelixNano will enter into a Sponsored Research Agreement with the University of Pittsburgh to conduct parts of the project under the direction of Dr. Lou Falo [6]. - HelixNano will supply the clinical drug product HN-0001 for the project, while the University will optimize the incorporation of this product into microneedle arrays [7][8]. Group 4: Non-Binding Nature of the MoU - The MoU is non-binding and does not obligate either party to proceed with the joint venture or any further development until definitive agreements are executed [9].

Core Points - Medicus Pharma Ltd. held its annual and special meeting of shareholders on July 22, 2025, where all resolutions were passed [1] - The company elected all eight nominees for the board of directors, including Congresswoman Cathy McMorris Rodgers and Ajay Raju [2][3] - The shareholders expressed pride in electing a diverse and experienced leadership team in drug development and governance [2] Board Members - Congresswoman Cathy McMorris Rodgers has a distinguished record in public service, serving as a U.S. Representative for Washington's 5th Congressional District from 2004 to 2025 [4][5] - Ajay Raju is an attorney and venture capitalist with extensive experience in structured finance, real estate, and life sciences [8] - Dr. Raza Bokhari serves as Executive Chairman and CEO, with a background in life sciences and healthcare services [9][10] - Other continuing board members include Dr. Larry Kaiser, Robert J. Ciaruffoli, William L. Ashton, Barry Fishman, and Dr. Sara R. May, each bringing significant experience in their respective fields [13][14][15][16][17] Shareholder Approvals - Shareholders approved the appointment of KPMG LLP as auditors and authorized the board to fix the auditors' remuneration [18] - An amendment to the company's by-laws was approved to increase the quorum requirement for shareholder meetings [18] - Approval was granted for the issuance of common shares under the Standby Equity Purchase Agreement, which may exceed 20% of the outstanding shares [18] - An amendment to increase the voting threshold required to remove the Chairman of the Board to 75% was also approved [18] Company Overview - Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating clinical development programs for novel therapeutics [20] - The company is engaged in multiple countries across three continents [20] - SkinJect Inc., a subsidiary of Medicus, is developing a non-invasive treatment for basal cell skin cancer using a dissolvable microneedle patch [21] - The company announced a definitive agreement to acquire Antev, a UK-based biotech company, which is subject to certain closing conditions [22]

Core Viewpoint - Medicus Pharma Ltd. is actively engaging in clinical development for innovative treatments in oncology and urology, with significant upcoming events and ongoing studies that may impact its market position and growth potential [1][6]. Group 1: Company Events - Medicus Pharma Ltd. will participate in the BTIG Virtual Biotech Conference 2025, with Dr. Raza Bokhari, Executive Chairman and CEO, scheduled for a Fireside Chat on July 30, 2025, at 9:20 a.m. ET [1][2]. - The Fireside Chat will be livestreamed for registered investors, and a recording will be available post-event [2]. Group 2: Clinical Development - The company's lead asset, SkinJect Inc., is focused on a novel treatment for non-melanoma skin cancer, particularly basal cell carcinoma (BCC), utilizing a patented dissolvable doxorubicin-containing microneedle array (D-MNA) [3][9]. - A Phase 2 clinical study (SKNJCT-003) is currently underway across nine clinical sites in the U.S., with an interim analysis showing over 60% clinical clearance after randomizing more than 50% of the targeted 60 patients [4]. - The investigational review board has increased the participant count for SKNJCT-003 to 90 subjects, and the company is also expanding clinical trial sites into Europe [4]. - A separate clinical study (SKNJCT-004) is being conducted in the UAE, randomizing 36 patients across four sites, with Cleveland Clinic Abu Dhabi as the principal investigator [5]. Group 3: Strategic Acquisitions - In June 2025, Medicus Pharma Ltd. announced a definitive agreement to acquire Antev Ltd., a UK-based clinical stage biotech company developing Teverelix for advanced prostate cancer patients [6][10]. - The acquisition is expected to close before the end of August 2025, subject to certain conditions including shareholder approval [6][10].

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive focuses on sectors such as biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] Group 2 - Proactive is a forward-looking company that adopts technology enthusiastically, utilizing decades of expertise and experience [4] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Core Viewpoint - Medicus Pharma Ltd. has submitted a request for a Type C meeting with the FDA to discuss the fast-tracking of its clinical development program for treating Basal Cell Carcinoma (BCC) using Dissolvable Doxorubicin-containing Microneedle Arrays (D-MNA) [1][2] Group 1: Clinical Development Program - The Type C meeting aims to align on the clinical pathway and seek FDA feedback on the D-MNA product development [2] - The clinical study SKNJCT-003 is a randomized, double-blind, placebo-controlled trial enrolling up to 60 subjects with BCC, evaluating two dose levels of D-MNA against a placebo [2][5] - The high-dose of 200μg D-MNA is the maximum dose used in the previous Phase 1 safety study, which was completed in March 2021 [3][5] Group 2: Study Design and Objectives - The company seeks FDA agreement on several key topics, including the appropriateness of selected doses, primary endpoints, patient population definitions, study design, and safety assessments for future studies [4] - The Phase 1 study (SKNJCT-001) met its primary objective of safety and tolerability, with no serious adverse events reported and six participants achieving complete responses [5][10] Group 3: Ongoing and Future Studies - The Phase 2 clinical study (SKNJCT-003) is currently underway at nine clinical sites in the U.S., with an interim analysis showing over 60% clinical clearance [6] - The number of participants in SKNJCT-003 has been increased to 90, and the company is expanding clinical trial sites to Europe [6] - A separate clinical study (SKNJCT-004) is being conducted in the UAE, aiming to randomize 36 patients across four sites [7] Group 4: Strategic Acquisitions - In June 2025, the company announced a definitive agreement to acquire Antev Limited, a UK-based biotech company developing Teverelix for advanced prostate cancer [8][11]

Company Developments - Medicus Pharma has entered into a definitive agreement to acquire Antev, a UK-based company focused on advancing clinical programs for two indications [1][3]. - Antev is developing a next-generation gonadotropin-releasing hormone therapy for advanced prostate cancer in patients with high cardiovascular risk, as well as a novel noninvasive treatment to prevent relapse of acute urinary retention [1][3]. Strategic Alignment - The acquisition of Antev aligns with Medicus Pharma's strategy to identify and integrate novel assets that address unmet medical needs [3][5]. - Antev will operate as a wholly owned subsidiary based in the UK, complementing Medicus Pharma's existing flagship asset, SKNJCT, which is also progressing with a Phase 2 study [4][5]. Management Enhancements - Medicus Pharma has appointed Andrew Smith as the new Chief Operating Officer, bringing significant experience in capital markets to strengthen the management team [6]. - The company is also enhancing its board with the addition of Congresswoman Cathy McMorris Rodgers, who has extensive experience with the FDA, which is expected to improve interactions with the regulatory body [6].

Company Overview - Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutic assets [1] Recent Developments - The company was established in October 2023 as a result of a merger or significant corporate restructuring [1]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's editorial operations span key finance and investing hubs with offices in London, New York, Toronto, Vancouver, Sydney, and Perth [2] Group 2 - The company utilizes technology to enhance workflows and has a forward-looking approach to technology adoption [4] - Proactive employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5] - The team produces around 50,000 pieces of real-time news, feature articles, and filmed interviews annually [1]

Core Viewpoint - Medicus Pharma Ltd has entered into a definitive agreement to acquire Antev Ltd, a UK-based clinical-stage drug development company, with Antev shareholders receiving approximately 17% equity stake in Medicus and up to US$65 million in contingent payments tied to future FDA approvals [1][4]. Group 1: Transaction Details - Medicus will acquire all issued and outstanding Antev Shares in exchange for 2,666,600 Medicus common shares, representing approximately 17% of the total shares [2]. - The transaction is expected to close by the end of August 2025, pending certain closing conditions including shareholder approval [5]. - Antev shareholders will be subject to a 9-month staggered lock-up and will grant voting rights to Medicus management for 36 months [3]. Group 2: Antev's Product Pipeline - Antev is developing Teverelix, a next-generation GnRH antagonist, targeting high-risk prostate cancer patients and those experiencing acute urinary retention due to enlarged prostate [6][14]. - Teverelix aims to prevent recurrence of acute urinary retention in men aged 45 and older, with a potential market opportunity exceeding US$2 billion annually [7]. - The FDA has approved a Phase 2b study for Teverelix in acute urinary retention, involving 390 participants [19]. Group 3: Market Potential - For advanced prostate cancer patients with increased cardiovascular risk, Teverelix presents a potential market opportunity of over US$4 billion annually, targeting 300,000 to 500,000 men in the US [10]. - Teverelix is designed to provide a hormone therapy option with potentially lower cardiac toxicity compared to conventional treatments [15]. Group 4: Clinical Development - Antev has completed a Phase 1 clinical trial for Teverelix, demonstrating good tolerance and rapid testosterone suppression [16]. - The company has also completed a Phase 2a study, achieving a primary endpoint of over 90% testosterone suppression but not maintaining this rate beyond 42 days [17]. - The FDA has provided guidance on Antev's proposed Phase 3 trial design for Teverelix, supporting its clinical development plans [18].

Core Insights - Medicus Pharma Ltd. has appointed Andrew Smith as Chief Operating Officer, bringing over three decades of experience in asset management and financial operations [2][3] - The company is actively engaged in clinical development, particularly with its SKNJCT-003 Phase 2 clinical study for treating Basal Cell Carcinoma (BCC) using novel Doxorubicin Microneedle Arrays (D-MNA) [4][8] Company Leadership - Andrew Smith's previous roles include Chief Executive of SR Asset Management and Co-Head of Americas at Aberdeen Asset Management, highlighting his extensive leadership experience [2][3] - Dr. Raza Bokhari, Executive Chairman and CEO, expressed confidence in Smith's expertise as the company expands its operations across three continents [3] Clinical Development Updates - The SKNJCT-003 Phase 2 clinical study has randomized over 50 of the 90 expected patients, with a positive interim analysis showing more than 60% clinical clearance [4][8] - The study is being conducted at nine clinical sites across the United States, having commenced patient randomization in August 2024 [4] - The investigational review board has increased the participant count for SKNJCT-003 from 60 to 90 subjects, and the company is also expanding clinical trial sites in Europe [4] Additional Clinical Studies - Medicus Pharma is conducting another clinical study, SKNJCT-004, in the United Arab Emirates, which aims to randomize 36 patients across four sites [5] - The principal investigator for the UAE study is Cleveland Clinic Abu Dhabi, with coordination by Insights Research Organization and Solutions [5] Acquisition Plans - The company has entered into a binding letter of intent to acquire Antev Ltd., a UK-based biotech company developing Teverelix for advanced prostate cancer patients [6][9] - The acquisition is subject to due diligence, negotiation of definitive agreements, and regulatory approvals [9]